Randomized phase II study of everolimus (E) versus everolimus plus bevacizumab (E plus B) in patients (Pts) with locally advanced or metastatic pancreatic neuroendocrine tumors (pNET), CALGB 80701 (Alliance) Kulke, M. H., Niedzwiecki, D., Foster, N. R., Fruth, B., Kunz, P. L., Kennecke, H. F., Wolin, E. M., Venook, A. P. AMER SOC CLINICAL ONCOLOGY. 2015

View details for DOI 10.1200/jco.2015.33.15_suppl.4005

View details for Web of Science ID 000358036900844